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ABSTRAK
Latar belakang: Alfakalsidol, suatu analog vitamin D, menunjukkan potensi regulasi imun saat bekerja pada 
makrofag dan sel T untuk mengontrol peradangan dan disregulasi sel T pada lansia. Saat ini belum diketahui 
efeknya pada orang tua dengan berbagai keadaan sindrom frailty yang memiliki peradangan kronis tingkat rendah 
yang berbeda. Penelitian ini bertujuan untuk mengetahui pengaruh alfakalsidol pada sitokin inflamasi (IL-6, IL-
10, g-IFN) dan subset sel T (CD4/CD8 rasio dan CD8 + CD28-) lansia dengan berbagai status sindrom frailty. 
Metode: selama Januari hingga Juli 2017, uji coba terkontrol acak buta ganda (RCT) dengan penyembunyian 
alokasi, melibatkan 110 subjek lansia dari Poliklinik Geriatri RS Cipto Mangunkusumo Jakarta, dilakukan untuk 
mengukur efek pemberian alfakalsidol 0,5 mcg selama 90 hari terhadap inflamasi. Pengukuran sitokin (IL-6, IL-10, 
g-IFN) dari supernatan kultur PBMC, serta persentase CD4/CD8 dan CD8+ CD28- menggunakan flow cytometry 
dilakukan. Analisis statistik menggunakan SPSS versi 20 dilakukan dengan t-test untuk mengukur perbedaan 
rata-rata. Hasil: dari 110 subjek yang terlibat dalam RCT yang terdiri dari 27 orang sehat, 27 pra-lemah dan 
56 orang lanjut usia lemah, 25 (OH) D serum adalah 25,59 (12,2) ng/ml dalam kelompok alfakalsidol dan 28,27 
(10.4) ng / ml dalam kelompok plasebo. Alfakalsidol tidak menurunkan IL-6 (p=0,4) dan g-IFN (p=0,001), tetapi 
meningkatkan IL-10 (p=0,005) dan menurunkan rasio IL6/IL10 (p=0,008). Alfakalsidol meningkatkan rasio CD4/
CD8 dari 2,68 (SD 2,45) menjadi 3,2 (SD 2,9); p=0,001 dan penurunan CD8+ CD28- persentase dari 5,1 (SD 
3,96) menjadi 2,5 (1,5); p<0,001. Analisis sub kelompok menunjukkan pola yang sama di semua status frailty. 
Kesimpulan: alfakalsidol meningkatkan penuaan kekebalan dengan bertindak sebagai agen anti-inflamasi melalui 
peningkatan IL-10 dan penurunan rasio IL6/IL-10 dan juga meningkatkan imunitas seluler melalui peningkatan 
rasio CD4/CD8 dan penurunan CD8+ CD28-subset pada lansia. Efek ini tidak dipengaruhi oleh status frailty.
Kata kunci: Alfakalsidol, inflamasi, sel T, usia lanjut, frailty.
ABSTRACT
Background: Alphacalcidol, a vitamin D analog, shows immune regulatory potency as it works on the 
macrophage and T cell to control inflammation and T cell dysregulation in elderly. None has been known about its 
effect on elderly with various states of frailty syndrome, which have different level of chronic low grade inflammation. 
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This study aimed to determine the effect of alphacalcidol on inflammatory cytokines (IL-6, IL-10, g-IFN ) and T 
cell subsets (CD4/CD8 ratio and CD8+ CD28-) of elderly with various stages of frailty syndrome. Methods: from 
January to July 2017, a double blind randomized controlled trial (RCT) with allocation concealment, involving 
110 elderly subjects from Geriatric Outpatient Clinic Cipto Mangunkusumo Hospital Jakarta, was conducted to 
measure the effect of 0.5 mcg alphacalcidol administration for 90 days to inflammatory cytokines (IL-6, IL-10, 
g-IFN) from PBMC culture supernatant, as well as CD4/CD8 and CD8+CD28- percentage using flow cytometry. 
Statistical analysis using SPSS version 20 was performed with t-test to measure mean difference. Results: of 110 
subjects involved in the RCT consisting of 27 fit, 27 pre-frail  and 56 frail elderly, 25(OH)D serum level was found 
to be as low as 25.59 (12.2) ng/ml in alphacalcidol group and 28.27 (10.4) ng/ml in placebo group. Alphacalcidol 
did not decrease IL-6 (p=0.4) and g- IFN (p=0.001), but it increased IL-10 (p=0,005) and decreased IL6/IL10 ratio 
(p=0.008). Alphacalcidol increased CD4/CD8 ratio from 2.68 (SD 2.45) to 3.2 (SD 2.9); p=0.001 and decreased 
CD8+ CD28- percentage from 5.1 (SD 3.96) to 2.5 (1.5); p<0.001. Sub group analysis showed similar patterns 
in all frailty states. Conclusion: Alphacalcidol improves immune senescence by acting as anti-inflammatory agent 
through increased IL-10 and decreased IL6/IL-10 ratio and also improves cellular immunity through increased 
CD4/CD8 ratio and decreased CD8+ CD28- subset in elderly. This effect is not influenced by frailty state.
Keywords: Alphacalcidol, inflammation, T cell, elderly, frailty.
INTRODUCTION
Although the term of immune senescence 
has been widely accepted to describe immune 
dysregulation in elderly, not much has been 
known about immune dysregulation in frail 
elder people.1-5 Frailty syndrome not only will 
lead to impairment of specific but also non 
specific immunity, which will be more severe 
than immunity dysregulation on healthy elderly.6 
Two substantial  immune senescence concepts in 
patient with frailty syndrome are inflammaging 
and immune risk profile (IRP). Inflammaging 
corresponds to the increasing of various pro 
inflammatory cytokines and the low production 
of anti-inflammatory cytokines in respond to 
infection stimulus while specific immunity system 
dysregulation described by IRP corresponds to 
the lower CD4/CD8 ratio besides the decreasing 
amount of T CD8+CD28+ cells.7
The benefit of vitamin D in improving the 
immune system dysregulation on elderly is 
achieved through its mechanism of inhibiting 
the excessive production of pro inflammatory 
cytokine by monocyte and macrophage through 
MAP phosphokinase 1 (MAPK-1) pathway.8 
Moreover, vitamin D directly and indirectly 
works on T cells.9 Systematic review assessing 
the effect of vitamin D on infectious disease 
shows conflicting result, but none of the trials 
involved frail elderly as subjects.10 The objective 
of this study was to determine the benefit of 
alphacalcidol, a vitamin D analog on frail elderly 
immune system dysregulation. Alphacalcidol, 
a vitamin D analog was chosen in this study 
because besides having lower hypercalcemia 
risk, it does not need hydroxylation in kidney 
thus should be safer for elderly patients with 
kidney impairment, and was expected to be more 
potent on immune cells.
METHODS
A total of 134 elderly subjects aged >60 years 
old who visited Geriatrics Outpatient Clinic 
in Cipto Mangunkusumo National Hospital 
Jakarta Indonesia from January to July 2017 
were recruited into this double blind placebo-
controlled alphacalcidol intervention study. 
Inclusion criteria was patient aged >60 year who 
agreed to be involved in the study. Exclusion 
criteria was hypercalcemia, consumption of 
NSAID, steroid, hydroxychloroquine, presence 
of  acute inflammation (based on medical 
history, physical or laboratory examination), 
autoimmune disease and malignancy.
Ethics
All subjects provided written informed 
consent before joining the trial. This trial was 
conducted according the principles of the 
Helsinki Declaration and had received ethical 
approval from Faculty of Medicine Universitas 
Indonesia (No 706/UN2.F1/ETIK/2016). This 
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trial was registered on clinicaltrials.gov (ID 
NCT0392744).
Intervention
Subjects were randomized to either 
intervention group receiving alphacalcidol 0.5 
mcg daily for 90 days or the placebo group 
receiving equivalent number of identical 
placebo capsules for 90 days. All subjects were 
instructed to consume the capsule once daily and 
maintain their usual diet and physical activity 
habits. Randomization was performed by an 
independent researcher using a computerized 
random sequence generation program. Subjects, 
investigators and outcome assessors were 
blinded and allocation concealment was 
performed. Caregivers were involved to ensure 
drug consumption by marking a tick on the 
drug logbook. Compliance was assessed by 
evaluating drug consumption log book, counting 
the drugs left in the drug container returned 
by the subjects every 30 days and measuring 
Parathyroid Hormone (PTH) concentration on 
day 0 dan 90. Good compliance was indicated 
by taking 90% of the prescribed drugs as shown 
in drug log book.
Data Collection and Analysis
Medical history and physical examination, 
including frailty state assessment using 
Cardiovascular Health Study criteria were 
obtained from eligible subjects. Frailty was defined 
as clinical syndrome in which three or more of 
the following criteria were present: unintentional 
weight loss, self-reported exhaustion, weakness, 
as well as slow walking speed and low physical 
activity. Subjects with 1 or 2 criteria were 
considered pre-frail and those without any criteria 
were considered fit. All participants were assessed 
with Barthel Activity of Daily Living to evaluate 
independency: food recall for assessment of 
dietary pattern and Mini Nutritional Assessment 
for nutritional status assessment. Sign and 
symptoms of acute condition that may change the 
immune response were recorded every 2 weeks.
Blood Sample Analysis
Blood were drawn on baseline (day 0) and 
after intervention (day 90)  for measurement 
of 25(OH), calcium and PTH concentration in 




Alphacalcidol 0.5 mcg for 90 days
(n=55)
Placebo for 90 days (n=55)
Loss to follow up (n=0)








- Bad compliance (n=1)
Analyzed (n=55) Analyzed (n=55)
FOLLOW UP
ANALYSIS
- Having acute disease
(n=8), using NSAID
(n=9)
- Refuse to join research
(n=7)
ALLOCATION
Figure 1. Flowchart of the subjets allocation
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serum, whole blood were taken for peripheral 
blood mononuclear cells (PBMC) isolation and 
culture. Blood serum were drawn also on day 
30 and 60 for calcium measurement. Serum 
25(OH)D were measured using ELISA with 
inter- and intra assay coefficients of variation 
of <10% and <4%. IL-6, IL-10 and g-IFN from 
culture supernatant were measured using R&D 
commercial ELISA kits and percentage of CD4, 
CD8, CD8+ CD28- T cell was measured from 
culture pellet  with flow citometry.
PBMC Culture and Isolation
PBMC were isolated by centrifuging 
fasting whole blood samples collected in BC 
Vacutainer cell preparation tubes  with heparin. 
The harvested PBMC pellet was re-suspended 
in RPMI medium with 10% dimethyl sulphoxide 
(DMSO) and stored at -80 C. Immediately prior 
to analysis, PBMC samples were thawed and 
washed in excess phosphate buffered saline 
(PBS) and centrifuged (400 g, 5 minutes 40C) 
to remove residual RPMI and DMSO. The 
supernatant was discarded and the pellet re-
suspended in 100 mcl of triple detergent buffer. 
Statistical Analysis
Analysis were performed on an intention 
to treat basis using SPSS version 20. Shapiro- 
Wilk test and visual inspection on histograms 
and scatterplots were used to assess normality. 
Baseline characteristics are presented as mean + 
SD and frequencies (%) or median (interquartile 
range (IQR) for skewed variables. Independent 
t test was used to examine the mean difference 
among variables. Efficacy of the intervention on 
the outcomes (between-group differences) were 
analyzed using changes in outcome variables. All 
tests were two sided and statistical significance 
was set at p <0.05.
RESULTS
From January to July 2017, 134 elderly 
subjects were screened, and there were 110 
patients eligible for the research. These subjects 
were randomized into 2 group. (Figure 1)
Mean age of the subjects were 73.5 (SD 
5,5) year. Most (73,6%) were woman and frail 
(52%). Patients with vitamin D insufficiency 
was 85%. Baseline demographic, clinical and 






Age (year), mean (SD) 73.4 (4.5) 73.7 (4.9)
Gender, n (%)
 - Male (n=29) 14 (35) 15 (28)
 - Female (n=81) 41 (65) 40 (72)
Education
 - Primary school 0 (0) 0 (0)
 - Secondary school 13 (23) 8 (14)
 - High school 42 (76) 47 (85)
Functional status
 - Independent 2 (3) 5 (9)
 - Low dependent 6 (10) 7 (12)
 - Intermediate dependent 35 (63) 30 (54)
 - Highly dependent 12 (21) 13 (23)
Body Mass Index  
(kg/m2), mean (SD) 21.7 (3.3) 22.3 (4.5)
Frailty state, n (%)
 - Fit (n=27) 13 (16) 14 (14)
 - Pre-frail (n=27) 12 (29) 15 (34)
 - Frail (n=56) 30 (54) 26 (50)
Serum 25(OH)D1 
(ng/ml), mean (SD) 27.59 (12.2) 28.27 (10.4)
Daily intake, mean (SD)
 - Energy (kkal) 1366.13 (76) 1202 (48.4)
 - Protein (gram) 46 (2.5) 49 (2.2)
 - Vitamin D (IU) 188 (21) 184 (22)
 - Calsium (mg) 302.5 (22) 387.5 (15.2)
Daily Sun exposure, n (%)
 - None 5 (9) 7 (12)
 - 0-30 min 28 (50) 29 (52)
 - 30-60 min 22 (41) 19 (34)
IL-6,(pg/ml), mean (SD) 36 (24.9) 35.2 (27.9)
IL-10 (pg/ml), mean (SD) 5.2 (2.0) 4.7 (2.2)
IL-6/IL-10 ratio, mean (SD) 4.7 (0.8) 3.2 (1.1)
g-IFN (pg/ml), mean (SD) 2.37 (1.1) 2.35 (0.7)
CD4 (%), mean (SD) 20.3 (0.8) 20.6 (1,0)
CD8 (%), mean (SD) 11.3 (0.7) 8.8 (0.3)
CD4/CD8 ratio, mean (SD) 2.66 (1.6) 2.68 (2.45)
CD8+ CD28- (%),  
mean (SD) 4.5 (2.2) 5.1 (3.9)
CD8+ CD28+ (%),  
mean (SD) 7.5 (0.4) 5.1 (0.2)
immunological characteristics of the subjects 
is shown in Table 1, After 90 days, cytokines 
from PBMC culture were measured as shown at 
Table 2. No subjects were showing signs and or 
symptoms of acute infection since 2 week before 
the end of the study (day 90).
Vol 50 • Number 3 • July 2018                    Effect of alfacalcidol on inflammatory markers and T cell subset in elderly
219
Table 2. Cytokine and T cell level on day 90
Immune 
parameter
Alfacalcidol Placebo P value
IL-6 control (pg/ml)
 - Control 38.2 (6.1) 33.0 (7.4) 0.4
 - +LPS 213 (7.2) 174 (7.2) 0.005
IL-10
 - Control 28.3 (13) 16.2 (1.9) 0.005
 - +LPS 70.3 (19) 55.0 (4.5) 0.02
g-IFN
 - Control 6.9 (3.4) 5.2 (3.4) 0.001
 - +LPS 7.3 (3.4) 11.7 (3.8) 0.001
IL-6/IL-10 ratio 3.56 (0.2) 3.87 (0.2) 0.008
CD4/CD8 ratio 3.2 (2.9) 1.81 (1.07) 0.001
CD8+ CD28- (%) 2.5 (1.5) 6.0 (3.72) <0.001
As shown on Table 2, alphacalcidol only 
increased IL-10 but it showed no effect on IL-6 
and g-IFN. Ratio of IL-6//IL-10 was decreasing 
in Alphacalcidol group. Similar pattern was found 
on subgroup analysis based on frailty state, as 
shown on Table 3. The decrease of CD4/CD8 
ratio was also clinically significant while its 
effect on CD8+ CD28- reduction percentage was 
modest. Adverse events were mild hypercalcemia 
in 3 subjects after 30 days of alphacalcidol use and 
one subject reported weakness with high normal 
calcium level. No serious adverse event was found 
during the research.
DISCUSSION
There were 2 pro-inflammatory cytokines 
studied in this trial. First was IL-6 which 
acts as anti inflammatory cytokine in acute 
inflammation and pro inflammatory cytokine in 
chronic inflammation. Second was g-IFN, the 
main pro-inflammatory cytokine secreted by T 
helper-1. Alphacalcidol did not decrease IL-6 in 
chronic and acute inflammation setting. To our 
knowledge, this study was the first reporting 
effect of alphacalcidol in inflammation profile 
in elder people of various frailty state. Other 
studies using different vitamin D preparations 
showed inconsistent results. Meta analysis from 
Calton of 12 trials showed basal IL-6 reduction 
after vitamin D intervention for minimum 12 
weeks.11 Other trial by Yusupov using 2000 
IU Vitamin D3 for 3 months concluded that 
vitamin D3 did not change inflammatory profile 
including IL-6.12 Alphacalcidol could not 
reduce IL-6 in chronic and acute inflammation 
probably due to several possible reasons. First, 
the duration and dose of alphacalcidol could 
not improve cytokine secretion impairment in 
most subjects on this study who were mostly 
in pre-frail and frail state. Second, based on 
research by Ojaimi, IL-6 reduced occurs while 
serum 25-(OH)D increased above 40 ng/ml.13 
In this trial considering alphacalcidol could 
not directly increase 25(OH)D as it would be 
very rapidly converted into 1.25 (OH)2D3, the 
25(OH)D sufficiency state could be reflected by 
the PTH level. PTH level on day 90 shows that 
the vitamin D insufficiency state had not been 
fully recovered. Third, difference in nutrient 
and vitamin D intake of Indonesian elderly 
which showed poor intake pattern probably also 
contributed to this immune profile. There was no 
effect on g-IFN found in this study, consistent 
with Yusupov who also found no effect on g-IFN 
using vitamin D3 preparation.13 Trial in Multiple 
Sclerosis patients by Mahon also did not find any 
benefit in term of g-IFN production.14
Alphacalcidol increased IL-10 in elderly. This 
finding is consistent with research by Yusupov13 
in healthy adults and Schleithoff15 in 123 patients 
Table 3. Subgroup analysis of inflammatory cytokines based on frailty state
Category Intervention
IL-6 (pg/ml), mean (SD) IL-10 (pg/ml), mean (SD) g-IFN (pg/ml), mean (SD)
Control LPS Control LPS Control LPS
Fit (n=27) Alphacalcidol 14.7 (6.4) 135 (3.0) 8.1 (0.2) 56.5 (2.8)* 3.1 (0.6) 7.0 (2.2)
Placebo 14.6 (7.6) 143 (7.1) 9.7 (1.1) 13.2 (0.6) 5.3 (0.92) 8.3 (0.50)
Pre-frail (n-27) Alphacalcidol 50.1 (3.3) 356.5 (18.7) 8,1 (16) 88.5 (4.5)* 2.4 (0.36) 6.9 (0.14)
Placebo 49.1 (6.1) 266 (8.3) 13.3 (0.7) 42.2 (2.87) 2.4 (0.3) 2.6 (0.92)
Frail (n=56) Alphacalcidol 30.1 (27.0) 247.6 (12.9) 11.9 (1.0) 87.2 (8.3)* 9.1 (0.55) 13.8 (0.54)
Placebo 40.6 (24.1) 43 (10.8) 24.2 (4.1) 59 (4.1) 4.6 (0.62) 5.3 (0.89)
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with chronic heart failure (CHF) using vitamin D 
for 9 months. Low anti-inflammation activity in 
elderly will cause prolonged inflammation leading 
to more severe impact on host. Increase of anti-
inflammatory cytokine will improve the recovery 
from inflammation process. IL-10 increased by 
vitamin D was related with activation of Vitamin 
D Receptor (VDR) which will further suppress 
IL-10 promotor gene and enhance upregulation 
of IL-10 production.16
Interestingly, this finding showed that 
alphacalcidol only influenced IL-10, did not seem 
to be influenced by difference of frailty state. 
Alphacalcidol could not improve IL-6 and g-IFN, 
showing that the pro-inflammatory state can not 
be affected through 3 months supplementation 
of alphacalcidol. However, decreased IL-6/
IL-10 ratio caused by alphacalcidol showed 
domination of anti-inflammatory property of 
alphacalcidol. Because in immune senescence 
low grade pro-inflammatory status exist with 
defect on anti-inflammatory response, this study 
might support the use of alphacalcidol for elderly 
in any frailty state.
CD4/CD8 ratio, which is also a predictor 
of negative health outcomes, was improved 
in alphacalcidol group. Vitamin D is known 
to have direct and indirect effect on T cells, 
through improvement of g-IFN  production by 
T helper 1. Percentage of CD8+ CD28- was also 
decreased by alphacalcidol. However, as the 
mean percentage at baseline was still below 30%, 
this effect still had no clinical implication. CD8+ 
CD28- T cell have negative impact in immune 
response through several mechanisms which 
will cause defect on general cellular response in 
elderly. CD28- T cell will expand oligoclonally 
occupy available space thus other subset will 
be decreased in number. CD8+ CD28- decrease 
means lower immune suppressive condition and 
better response to vaccination.17
This study, to the extent of authors knowledge, 
was the first to examine the effect of alphacalcidol 
in immune response involving frail elder subjects, 
in which in many trials, frail elderly were 
generally excluded. Limitation of this study was 
that cytokine measurements were only conducted 
before and after intervention thus the kinetics of 
cytokine secretion could not be observed.
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